Sponsored

The field of women’s health suffers from a lack of specific and standardized tools optimized for the study of the human vaginal microbiome. Learn about the OMNIgene™•VAGINAL device for the self-collection and stabilization of vaginal samples, and OMNIgene™•XTRACT ULTRA extraction kits for the recovery of vaginal microbial DNA and RNA to support vaginal microbiome discovery.

The OMNIgene™•XTRACT ULTRA kit enables the optimal recovery of large quantities of high-quality DNA and RNA from a wide range of sample types including vaginal samples collected with the OMNIgene™•VAGINAL device. The OMNIgene™•XTRACT ULTRA kit is the first solution validated to provide significantly higher DNA and RNA yields from vaginal samples to better support multi-omic analysis of microbial communities.

Perfecting microbial manufacturing processes means taming its greatest asset: speed. This rapid process for creating biologics also means a race against time, where success hinges on conquering three key challenges: designing a robust microbial strain, optimizing fermentation for industrial scale, and ensuring consistent high-yield product yield.

Optimization Through Culture, Quality Control and Regulatory Standards

Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study

The vaginal microbiome plays a critical role in women’s health, from infection resistance to fertility, yet it continues to remain underexplored. With DNA Genotek™’s OMNIgene™•VAGINAL collection kit, researchers and innovators are empowered to collect stablized samples with precision to support women’s healthcare research and development of healthcare for women.

This year, LOTTE BIOLOGICS has ramped up its CDMO business expansion with the completion of an ADC (Antibody-Drug Conjugate) facility expansion at its Syracuse Bio Campus in the U.S. and the signing of its first production contract.

In the United States, only 31.4 % of phase II/III clinical trials in oncology are successfully completed¹. The causes of this dramatic economic and time-consuming loss are, among others, protocol design and patient recruitment challenges.

The 2025 BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S. time) at the Boston Convention & Exhibition Center. This year, Taipei City Government is partnering with six Taipei-based biotech companies, including PanCAD.ai Co., Ltd., Instant NanoBiosensors Co., Ltd., Bened Biomedical Co., Ltd., Cancer Free Biotech Ltd., Xantho Biotechnology Co., Ltd., and Energenesis Biomedical Co., Ltd., to showcase their innovations at the Taiwan Pavilion (Booth #1645) in the Taipei Exhibition Area.